As per our research, the size of the Protein A Resins Market in Europe was worth $ 95.43 million in 2019 and estimated to be growing at a CAGR of 7.8%, to reach $138.92 million by 2024.
The market is showing evident potential in the mentioned forecast period. Increasing research and development activities on monoclonal antibodies is expected to drive sales of Protein A resins in the future.
Monoclonal antibodies can be defined as an antibody produced by a single clone of cells; these antibodies can be produced in large quantities in the laboratory. They can be used to carry drugs, toxins, or radioactive substances straight to cancer cells. Monoclonal antibodies have been showing promising results in the management of chronic diseases such as cancers and rheumatoid arthritis.
The European market for Protein A Resins is driven by factors such as growing demand for biosimilars and increasing investments into the research and development of biosimilar products while increasing awareness about alternate methods to purify monoclonal antibodies is anticipated to hamper the growth of Protein A Resins market. Another major factor restraining the growth of Protein A resins market is the high cost of these products.
This research report segmented and sub-segmented into the following categories:
Regionally, Europe is the second-largest market for Protein A resin accounting for a share of approximately XX%. Within Europe, the United Kingdom is the largest market for Protein A resins whereas Germany is estimated to be the fastest-growing region.
Key players operating in the Europe Protein A Resins Market profiled in this report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific and EMD Millipore and Expedeon Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Natural Protein A Resin
5.1.2 Recombinant Protein A Resin
5.2 By Application
5.2.1 Immunoprecipitation
5.2.2 Antibody Purification
5.3 By End Users
5.3.1 Biopharmaceutical Manufacturers
5.3.2 Clinical Research Laboratories
5.3.3 Academic Institutes
5.4 By Matrix Type
5.4.1 Glass or Silica
5.4.2 Agarose
5.4.3 Organic Polymer
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fisher Scientific
8.3 Repligen
8.4 Tosoh Bioscience
8.5 EMD Millipore
8.6 Novasep
8.7 GenScript
8.8 Expedeon Ltd
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
